Ex vivo culture of pancreatic tumor slices for CAR-T therapy optimization
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of pancreatic cancer for which there are limited therapeutic interventions. In order to develop therapies and determine individual patient response it is vital to develop physiologically representative models. Ex vivo culture of pancreatic tumor slices fulfills this requirement by maintaining the structural integrity and cellular diversity of the tumor, including stromal cell populations and resident immune cells. Dynamic perfusion prevents sheer stress through media change and maintains consistent nutrient delivery and waste disposal. This technology, combined with analysis of resident immune cell phenotype, will be used to investigate the effects of immune agonists in the context of PDAC treatment. Additionally, it has the potential to allow analysis of emerging chimeric antigen receptor (CAR) T cell platforms in a clinically relevant setting.
I graduated from The University of Oxford with a degree in Biomedical Sciences, focusing on Immunology, Virology and Oncology. I have previously worked with The University of Birmingham, researching the dynamics of the PEAR1 pathway of platelet aggregation in the Institute of Cardiovascular Sciences. I also undertook a project at The Dunn School of Pathology using iPSC-derived macrophages to investigate the role of STING activation in neural inflammation in Parkinson's disease. I am currently a first year DPhil student and freelance science writer for Apeiron Biologics.